nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Ill-defined disorder—Cisplatin—testicular cancer	0.00314	0.00314	CcSEcCtD
Apraclonidine—Skin disorder—Ifosfamide—testicular cancer	0.00312	0.00312	CcSEcCtD
Apraclonidine—Feeling abnormal—Bleomycin—testicular cancer	0.00309	0.00309	CcSEcCtD
Apraclonidine—Vomiting—Chlorambucil—testicular cancer	0.00308	0.00308	CcSEcCtD
Apraclonidine—Malaise—Cisplatin—testicular cancer	0.00306	0.00306	CcSEcCtD
Apraclonidine—Diarrhoea—Vinblastine—testicular cancer	0.00304	0.00304	CcSEcCtD
Apraclonidine—Dysgeusia—Etoposide—testicular cancer	0.00304	0.00304	CcSEcCtD
Apraclonidine—Fatigue—Dactinomycin—testicular cancer	0.00302	0.00302	CcSEcCtD
Apraclonidine—Pain—Dactinomycin—testicular cancer	0.00299	0.00299	CcSEcCtD
Apraclonidine—Eye pain—Doxorubicin—testicular cancer	0.00296	0.00296	CcSEcCtD
Apraclonidine—Irritability—Methotrexate—testicular cancer	0.00295	0.00295	CcSEcCtD
Apraclonidine—Dizziness—Vinblastine—testicular cancer	0.00294	0.00294	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00292	0.00292	CcSEcCtD
Apraclonidine—Myalgia—Cisplatin—testicular cancer	0.00289	0.00289	CcSEcCtD
Apraclonidine—Feeling abnormal—Dactinomycin—testicular cancer	0.00289	0.00289	CcSEcCtD
Apraclonidine—Nausea—Chlorambucil—testicular cancer	0.00288	0.00288	CcSEcCtD
Apraclonidine—Paraesthesia—Ifosfamide—testicular cancer	0.00288	0.00288	CcSEcCtD
Apraclonidine—Ill-defined disorder—Etoposide—testicular cancer	0.00288	0.00288	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00287	0.00287	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00286	0.00286	CcSEcCtD
Apraclonidine—Dyspnoea—Ifosfamide—testicular cancer	0.00286	0.00286	CcSEcCtD
Apraclonidine—Somnolence—Ifosfamide—testicular cancer	0.00285	0.00285	CcSEcCtD
Apraclonidine—Discomfort—Cisplatin—testicular cancer	0.00285	0.00285	CcSEcCtD
Apraclonidine—Vomiting—Vinblastine—testicular cancer	0.00283	0.00283	CcSEcCtD
Apraclonidine—Malaise—Etoposide—testicular cancer	0.0028	0.0028	CcSEcCtD
Apraclonidine—Face oedema—Epirubicin—testicular cancer	0.00279	0.00279	CcSEcCtD
Apraclonidine—Headache—Vinblastine—testicular cancer	0.00278	0.00278	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00277	0.00277	CcSEcCtD
Apraclonidine—Abdominal pain—Dactinomycin—testicular cancer	0.00277	0.00277	CcSEcCtD
Apraclonidine—Fatigue—Ifosfamide—testicular cancer	0.00277	0.00277	CcSEcCtD
Apraclonidine—Oedema—Cisplatin—testicular cancer	0.00277	0.00277	CcSEcCtD
Apraclonidine—Hypersensitivity—Bleomycin—testicular cancer	0.00277	0.00277	CcSEcCtD
Apraclonidine—Infection—Cisplatin—testicular cancer	0.00275	0.00275	CcSEcCtD
Apraclonidine—Constipation—Ifosfamide—testicular cancer	0.00274	0.00274	CcSEcCtD
Apraclonidine—Pain—Ifosfamide—testicular cancer	0.00274	0.00274	CcSEcCtD
Apraclonidine—Nervous system disorder—Cisplatin—testicular cancer	0.00271	0.00271	CcSEcCtD
Apraclonidine—Asthenia—Bleomycin—testicular cancer	0.00269	0.00269	CcSEcCtD
Apraclonidine—Skin disorder—Cisplatin—testicular cancer	0.00269	0.00269	CcSEcCtD
Apraclonidine—Asthma—Methotrexate—testicular cancer	0.00267	0.00267	CcSEcCtD
Apraclonidine—Pruritus—Bleomycin—testicular cancer	0.00266	0.00266	CcSEcCtD
Apraclonidine—Feeling abnormal—Ifosfamide—testicular cancer	0.00264	0.00264	CcSEcCtD
Apraclonidine—Chest pain—Etoposide—testicular cancer	0.00264	0.00264	CcSEcCtD
Apraclonidine—Nausea—Vinblastine—testicular cancer	0.00264	0.00264	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00263	0.00263	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00262	0.00262	CcSEcCtD
Apraclonidine—Discomfort—Etoposide—testicular cancer	0.00261	0.00261	CcSEcCtD
Apraclonidine—Nasopharyngitis—Epirubicin—testicular cancer	0.00258	0.00258	CcSEcCtD
Apraclonidine—Face oedema—Doxorubicin—testicular cancer	0.00258	0.00258	CcSEcCtD
Apraclonidine—Hypersensitivity—Dactinomycin—testicular cancer	0.00258	0.00258	CcSEcCtD
Apraclonidine—Abdominal discomfort—Methotrexate—testicular cancer	0.00256	0.00256	CcSEcCtD
Apraclonidine—Abdominal pain—Ifosfamide—testicular cancer	0.00254	0.00254	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00252	0.00252	CcSEcCtD
Apraclonidine—Infection—Etoposide—testicular cancer	0.00252	0.00252	CcSEcCtD
Apraclonidine—Asthenia—Dactinomycin—testicular cancer	0.00251	0.00251	CcSEcCtD
Apraclonidine—Asthma—Epirubicin—testicular cancer	0.0025	0.0025	CcSEcCtD
Apraclonidine—Paraesthesia—Cisplatin—testicular cancer	0.00248	0.00248	CcSEcCtD
Apraclonidine—Dyspnoea—Cisplatin—testicular cancer	0.00247	0.00247	CcSEcCtD
Apraclonidine—Skin disorder—Etoposide—testicular cancer	0.00246	0.00246	CcSEcCtD
Apraclonidine—Diarrhoea—Dactinomycin—testicular cancer	0.0024	0.0024	CcSEcCtD
Apraclonidine—Nasopharyngitis—Doxorubicin—testicular cancer	0.00239	0.00239	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00239	0.00239	CcSEcCtD
Apraclonidine—Vomiting—Bleomycin—testicular cancer	0.00239	0.00239	CcSEcCtD
Apraclonidine—Infestation NOS—Methotrexate—testicular cancer	0.00238	0.00238	CcSEcCtD
Apraclonidine—Infestation—Methotrexate—testicular cancer	0.00238	0.00238	CcSEcCtD
Apraclonidine—Pain—Cisplatin—testicular cancer	0.00237	0.00237	CcSEcCtD
Apraclonidine—Dermatitis—Bleomycin—testicular cancer	0.00236	0.00236	CcSEcCtD
Apraclonidine—Hypersensitivity—Ifosfamide—testicular cancer	0.00236	0.00236	CcSEcCtD
Apraclonidine—Conjunctivitis—Methotrexate—testicular cancer	0.00231	0.00231	CcSEcCtD
Apraclonidine—Asthma—Doxorubicin—testicular cancer	0.00231	0.00231	CcSEcCtD
Apraclonidine—Asthenia—Ifosfamide—testicular cancer	0.0023	0.0023	CcSEcCtD
Apraclonidine—Feeling abnormal—Cisplatin—testicular cancer	0.00228	0.00228	CcSEcCtD
Apraclonidine—Paraesthesia—Etoposide—testicular cancer	0.00228	0.00228	CcSEcCtD
Apraclonidine—Pruritus—Ifosfamide—testicular cancer	0.00227	0.00227	CcSEcCtD
Apraclonidine—Dyspnoea—Etoposide—testicular cancer	0.00226	0.00226	CcSEcCtD
Apraclonidine—Somnolence—Etoposide—testicular cancer	0.00225	0.00225	CcSEcCtD
Apraclonidine—Nausea—Bleomycin—testicular cancer	0.00223	0.00223	CcSEcCtD
Apraclonidine—Infestation—Epirubicin—testicular cancer	0.00223	0.00223	CcSEcCtD
Apraclonidine—Infestation NOS—Epirubicin—testicular cancer	0.00223	0.00223	CcSEcCtD
Apraclonidine—Vomiting—Dactinomycin—testicular cancer	0.00223	0.00223	CcSEcCtD
Apraclonidine—Diarrhoea—Ifosfamide—testicular cancer	0.0022	0.0022	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Etoposide—testicular cancer	0.00219	0.00219	CcSEcCtD
Apraclonidine—Fatigue—Etoposide—testicular cancer	0.00218	0.00218	CcSEcCtD
Apraclonidine—Constipation—Etoposide—testicular cancer	0.00217	0.00217	CcSEcCtD
Apraclonidine—Pain—Etoposide—testicular cancer	0.00217	0.00217	CcSEcCtD
Apraclonidine—Conjunctivitis—Epirubicin—testicular cancer	0.00216	0.00216	CcSEcCtD
Apraclonidine—Haemorrhage—Methotrexate—testicular cancer	0.00214	0.00214	CcSEcCtD
Apraclonidine—Dizziness—Ifosfamide—testicular cancer	0.00212	0.00212	CcSEcCtD
Apraclonidine—Pharyngitis—Methotrexate—testicular cancer	0.00212	0.00212	CcSEcCtD
Apraclonidine—Feeling abnormal—Etoposide—testicular cancer	0.00209	0.00209	CcSEcCtD
Apraclonidine—Nausea—Dactinomycin—testicular cancer	0.00208	0.00208	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Etoposide—testicular cancer	0.00207	0.00207	CcSEcCtD
Apraclonidine—Infestation—Doxorubicin—testicular cancer	0.00206	0.00206	CcSEcCtD
Apraclonidine—Infestation NOS—Doxorubicin—testicular cancer	0.00206	0.00206	CcSEcCtD
Apraclonidine—Visual impairment—Methotrexate—testicular cancer	0.00206	0.00206	CcSEcCtD
Apraclonidine—Vomiting—Ifosfamide—testicular cancer	0.00204	0.00204	CcSEcCtD
Apraclonidine—Hypersensitivity—Cisplatin—testicular cancer	0.00204	0.00204	CcSEcCtD
Apraclonidine—Bradycardia—Epirubicin—testicular cancer	0.00204	0.00204	CcSEcCtD
Apraclonidine—Dermatitis—Ifosfamide—testicular cancer	0.00202	0.00202	CcSEcCtD
Apraclonidine—Rhinitis—Epirubicin—testicular cancer	0.002	0.002	CcSEcCtD
Apraclonidine—Abdominal pain—Etoposide—testicular cancer	0.002	0.002	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—testicular cancer	0.002	0.002	CcSEcCtD
Apraclonidine—Haemorrhage—Epirubicin—testicular cancer	0.002	0.002	CcSEcCtD
Apraclonidine—Eye disorder—Methotrexate—testicular cancer	0.002	0.002	CcSEcCtD
Apraclonidine—Asthenia—Cisplatin—testicular cancer	0.00198	0.00198	CcSEcCtD
Apraclonidine—Pharyngitis—Epirubicin—testicular cancer	0.00198	0.00198	CcSEcCtD
Apraclonidine—Oedema peripheral—Epirubicin—testicular cancer	0.00197	0.00197	CcSEcCtD
Apraclonidine—Angiopathy—Methotrexate—testicular cancer	0.00194	0.00194	CcSEcCtD
Apraclonidine—Visual impairment—Epirubicin—testicular cancer	0.00193	0.00193	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methotrexate—testicular cancer	0.00193	0.00193	CcSEcCtD
Apraclonidine—Nausea—Ifosfamide—testicular cancer	0.00191	0.00191	CcSEcCtD
Apraclonidine—Diarrhoea—Cisplatin—testicular cancer	0.00189	0.00189	CcSEcCtD
Apraclonidine—Bradycardia—Doxorubicin—testicular cancer	0.00188	0.00188	CcSEcCtD
Apraclonidine—Mental disorder—Methotrexate—testicular cancer	0.00187	0.00187	CcSEcCtD
Apraclonidine—Eye disorder—Epirubicin—testicular cancer	0.00187	0.00187	CcSEcCtD
Apraclonidine—Hypersensitivity—Etoposide—testicular cancer	0.00187	0.00187	CcSEcCtD
Apraclonidine—Erythema—Methotrexate—testicular cancer	0.00186	0.00186	CcSEcCtD
Apraclonidine—Rhinitis—Doxorubicin—testicular cancer	0.00185	0.00185	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—testicular cancer	0.00185	0.00185	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—testicular cancer	0.00184	0.00184	CcSEcCtD
Apraclonidine—Oedema peripheral—Doxorubicin—testicular cancer	0.00182	0.00182	CcSEcCtD
Apraclonidine—Dysgeusia—Methotrexate—testicular cancer	0.00182	0.00182	CcSEcCtD
Apraclonidine—Asthenia—Etoposide—testicular cancer	0.00182	0.00182	CcSEcCtD
Apraclonidine—Angiopathy—Epirubicin—testicular cancer	0.00181	0.00181	CcSEcCtD
Apraclonidine—Mediastinal disorder—Epirubicin—testicular cancer	0.0018	0.0018	CcSEcCtD
Apraclonidine—Pruritus—Etoposide—testicular cancer	0.00179	0.00179	CcSEcCtD
Apraclonidine—Arrhythmia—Epirubicin—testicular cancer	0.00179	0.00179	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—testicular cancer	0.00178	0.00178	CcSEcCtD
Apraclonidine—Vomiting—Cisplatin—testicular cancer	0.00176	0.00176	CcSEcCtD
Apraclonidine—Vision blurred—Methotrexate—testicular cancer	0.00175	0.00175	CcSEcCtD
Apraclonidine—Mental disorder—Epirubicin—testicular cancer	0.00175	0.00175	CcSEcCtD
Apraclonidine—Dermatitis—Cisplatin—testicular cancer	0.00174	0.00174	CcSEcCtD
Apraclonidine—Erythema—Epirubicin—testicular cancer	0.00174	0.00174	CcSEcCtD
Apraclonidine—Diarrhoea—Etoposide—testicular cancer	0.00173	0.00173	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—testicular cancer	0.00173	0.00173	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methotrexate—testicular cancer	0.00173	0.00173	CcSEcCtD
Apraclonidine—Tension—Epirubicin—testicular cancer	0.00171	0.00171	CcSEcCtD
Apraclonidine—Dysgeusia—Epirubicin—testicular cancer	0.0017	0.0017	CcSEcCtD
Apraclonidine—Nervousness—Epirubicin—testicular cancer	0.00169	0.00169	CcSEcCtD
Apraclonidine—Angiopathy—Doxorubicin—testicular cancer	0.00168	0.00168	CcSEcCtD
Apraclonidine—Malaise—Methotrexate—testicular cancer	0.00168	0.00168	CcSEcCtD
Apraclonidine—Dizziness—Etoposide—testicular cancer	0.00168	0.00168	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—testicular cancer	0.00167	0.00167	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—testicular cancer	0.00165	0.00165	CcSEcCtD
Apraclonidine—Nausea—Cisplatin—testicular cancer	0.00164	0.00164	CcSEcCtD
Apraclonidine—Vision blurred—Epirubicin—testicular cancer	0.00164	0.00164	CcSEcCtD
Apraclonidine—Mental disorder—Doxorubicin—testicular cancer	0.00162	0.00162	CcSEcCtD
Apraclonidine—Ill-defined disorder—Epirubicin—testicular cancer	0.00161	0.00161	CcSEcCtD
Apraclonidine—Vomiting—Etoposide—testicular cancer	0.00161	0.00161	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—testicular cancer	0.00161	0.00161	CcSEcCtD
Apraclonidine—Dermatitis—Etoposide—testicular cancer	0.0016	0.0016	CcSEcCtD
Apraclonidine—Headache—Etoposide—testicular cancer	0.00159	0.00159	CcSEcCtD
Apraclonidine—Myalgia—Methotrexate—testicular cancer	0.00158	0.00158	CcSEcCtD
Apraclonidine—Chest pain—Methotrexate—testicular cancer	0.00158	0.00158	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—testicular cancer	0.00158	0.00158	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—testicular cancer	0.00158	0.00158	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00157	0.00157	CcSEcCtD
Apraclonidine—Malaise—Epirubicin—testicular cancer	0.00157	0.00157	CcSEcCtD
Apraclonidine—Discomfort—Methotrexate—testicular cancer	0.00156	0.00156	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—testicular cancer	0.00156	0.00156	CcSEcCtD
Apraclonidine—Syncope—Epirubicin—testicular cancer	0.00156	0.00156	CcSEcCtD
Apraclonidine—Palpitations—Epirubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—testicular cancer	0.00152	0.00152	CcSEcCtD
Apraclonidine—Infection—Methotrexate—testicular cancer	0.00151	0.00151	CcSEcCtD
Apraclonidine—Nausea—Etoposide—testicular cancer	0.00151	0.00151	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—testicular cancer	0.00149	0.00149	CcSEcCtD
Apraclonidine—Nervous system disorder—Methotrexate—testicular cancer	0.00149	0.00149	CcSEcCtD
Apraclonidine—Myalgia—Epirubicin—testicular cancer	0.00148	0.00148	CcSEcCtD
Apraclonidine—Chest pain—Epirubicin—testicular cancer	0.00148	0.00148	CcSEcCtD
Apraclonidine—Skin disorder—Methotrexate—testicular cancer	0.00147	0.00147	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Apraclonidine—Discomfort—Epirubicin—testicular cancer	0.00146	0.00146	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—testicular cancer	0.00145	0.00145	CcSEcCtD
Apraclonidine—Dry mouth—Epirubicin—testicular cancer	0.00145	0.00145	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—testicular cancer	0.00144	0.00144	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—testicular cancer	0.00142	0.00142	CcSEcCtD
Apraclonidine—Oedema—Epirubicin—testicular cancer	0.00142	0.00142	CcSEcCtD
Apraclonidine—Infection—Epirubicin—testicular cancer	0.00141	0.00141	CcSEcCtD
Apraclonidine—Nervous system disorder—Epirubicin—testicular cancer	0.00139	0.00139	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00138	0.00138	CcSEcCtD
Apraclonidine—Skin disorder—Epirubicin—testicular cancer	0.00138	0.00138	CcSEcCtD
Apraclonidine—Insomnia—Methotrexate—testicular cancer	0.00137	0.00137	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Apraclonidine—Paraesthesia—Methotrexate—testicular cancer	0.00136	0.00136	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—testicular cancer	0.00135	0.00135	CcSEcCtD
Apraclonidine—Dyspnoea—Methotrexate—testicular cancer	0.00135	0.00135	CcSEcCtD
Apraclonidine—Somnolence—Methotrexate—testicular cancer	0.00135	0.00135	CcSEcCtD
Apraclonidine—Dry mouth—Doxorubicin—testicular cancer	0.00134	0.00134	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00131	0.00131	CcSEcCtD
Apraclonidine—Fatigue—Methotrexate—testicular cancer	0.00131	0.00131	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Apraclonidine—Pain—Methotrexate—testicular cancer	0.0013	0.0013	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Apraclonidine—Insomnia—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Apraclonidine—Paraesthesia—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Apraclonidine—Dyspnoea—Epirubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Apraclonidine—Somnolence—Epirubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Apraclonidine—Feeling abnormal—Methotrexate—testicular cancer	0.00125	0.00125	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methotrexate—testicular cancer	0.00124	0.00124	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Apraclonidine—Fatigue—Epirubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Apraclonidine—Constipation—Epirubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Apraclonidine—Pain—Epirubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Apraclonidine—Abdominal pain—Methotrexate—testicular cancer	0.0012	0.0012	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Apraclonidine—Feeling abnormal—Epirubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Epirubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Apraclonidine—Abdominal pain—Epirubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Apraclonidine—Hypersensitivity—Methotrexate—testicular cancer	0.00112	0.00112	CcSEcCtD
Apraclonidine—Asthenia—Methotrexate—testicular cancer	0.00109	0.00109	CcSEcCtD
Apraclonidine—Feeling abnormal—Doxorubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Apraclonidine—Pruritus—Methotrexate—testicular cancer	0.00107	0.00107	CcSEcCtD
Apraclonidine—Hypersensitivity—Epirubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Apraclonidine—Diarrhoea—Methotrexate—testicular cancer	0.00104	0.00104	CcSEcCtD
Apraclonidine—Asthenia—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Apraclonidine—Pruritus—Epirubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Apraclonidine—Dizziness—Methotrexate—testicular cancer	0.001	0.001	CcSEcCtD
Apraclonidine—Diarrhoea—Epirubicin—testicular cancer	0.000972	0.000972	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—testicular cancer	0.000968	0.000968	CcSEcCtD
Apraclonidine—Vomiting—Methotrexate—testicular cancer	0.000965	0.000965	CcSEcCtD
Apraclonidine—Dermatitis—Methotrexate—testicular cancer	0.000956	0.000956	CcSEcCtD
Apraclonidine—Headache—Methotrexate—testicular cancer	0.000951	0.000951	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—testicular cancer	0.000943	0.000943	CcSEcCtD
Apraclonidine—Dizziness—Epirubicin—testicular cancer	0.000939	0.000939	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—testicular cancer	0.00093	0.00093	CcSEcCtD
Apraclonidine—Vomiting—Epirubicin—testicular cancer	0.000903	0.000903	CcSEcCtD
Apraclonidine—Nausea—Methotrexate—testicular cancer	0.000902	0.000902	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—testicular cancer	0.000899	0.000899	CcSEcCtD
Apraclonidine—Dermatitis—Epirubicin—testicular cancer	0.000895	0.000895	CcSEcCtD
Apraclonidine—Headache—Epirubicin—testicular cancer	0.00089	0.00089	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—testicular cancer	0.000869	0.000869	CcSEcCtD
Apraclonidine—Nausea—Epirubicin—testicular cancer	0.000844	0.000844	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—testicular cancer	0.000836	0.000836	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—testicular cancer	0.000828	0.000828	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—testicular cancer	0.000823	0.000823	CcSEcCtD
Apraclonidine—Nausea—Doxorubicin—testicular cancer	0.000781	0.000781	CcSEcCtD
